Status:
COMPLETED
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Lead Sponsor:
Amgen
Conditions:
Cardiovascular Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).
Eligibility Criteria
Inclusion
- Age 18 to 80 years
- Lipoprotein (a) \> 150 nmol/L
- Evidence of atherosclerotic cardiovascular disease
Exclusion
- Severe renal dysfunction
- History or clinical evidence of hepatic dysfunction
- Malignancy within the last 5 years
- Currently receiving, or less than 3 months at Day 1 since receiving \> 200 mg/day Niacin
Key Trial Info
Start Date :
July 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2022
Estimated Enrollment :
281 Patients enrolled
Trial Details
Trial ID
NCT04270760
Start Date
July 28 2020
End Date
November 8 2022
Last Update
May 9 2025
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Westside Medical Associates of Los Angeles
Beverly Hills, California, United States, 90211
2
Excel Medical Clinical Trials
Boca Raton, Florida, United States, 33434
3
Piedmont Healthcare
Atlanta, Georgia, United States, 30309
4
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160